ARCUTIS BIOTHERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $161.68M.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $161.66M.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2022-03-31 was $14.37M, a 93.08% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $207.49M, a 24.07% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2024 was $161.68M, a 5055.68% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $3.14M, a 98.06% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2022 was $161.66M, a 22.09% decline from fiscal 2021.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2021 was $207.49M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $161.68M 10-K · filed 2025-02-25 | |
| 2024-03-31 | $161.68M 10-Q · filed 2025-10-28 | |
| 2023-12-31 | $3.14M 10-K · filed 2026-02-25 | |
| 2022-12-31 | $161.66M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $161.66M 10-Q · filed 2023-11-03 | |
| 2022-03-31 | $14.37M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $207.49M 10-K · filed 2024-02-27 | |
| 2021-03-31 | $207.49M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $167.24M 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |